COVID-19 and Prostate Cancer: a Complex Scenario With Multiple Facets

Crocetto, Felice; Buonerba, Luciana; Scafuri, Luca; Caputo, Vincenzo; Barone, Biagio; Sciarra, A.; Verde, Antonio; Calogero, Armando; Buonerba, Carlo; Lorenzo, Giuseppe Di

doi:10.2144/fsoa-2021-0113

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, concerning the COVID-19 pandemic, it is important to discuss the influence on the clinical management of prostate cancer. The opinions of Crocetto and Di Lorenzo describe the clinical characteristics of prostate cancer patients who are COVID-19 positive ( 29 , 30 ). Although serum PSA screening for early PCa detection has been widespread in China, our study started in 2020, when the COVID-19 pandemic had begun.…”

Section: Discussionmentioning

confidence: 99%

Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection

Chen

Qian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEarly screening of clinically significant prostate cancer (csPCa) may offer opportunities in revolutionizing the survival benefits of this lethal disease. We sought to introduce a modified prostate health index density (mPHI) model using imaging indicators and to compare its diagnostic performance for early detection of occult onset csPCa within the prostate-specific antigen (PSA) gray zone with that of PHI and PHID.Methods and ParticipationBetween August 2020 and January 2022, a training cohort of 278 patients (total PSA 4.0–10.0 ng/ml) who were scheduled for a prostate biopsy were prospectively recruited. PHI and PHID were compared with mPHI (LDTRD×APD×TPV×PHI) for the diagnosis performance in identifying csPCa. Pathology outcomes from systematic prostate biopsies were considered the gold standard.ResultsThis model was tested in a training cohort consisting of 73 csPCa, 14 non-clinically significant prostate cancer(non-csPCa), and 191 benign prostatic hyperplasia (BPH) samples. In the univariate analysis for the PSA gray zone cohort, for overall PCa, the AUC of mPHI (0.856) was higher than PHI (0.774) and PHID (0.835). For csPCa, the AUC of mPHI (0.859) also surpassed PHI (0.787) and PHID (0.825). For detection of csPCa, compared with lower specificities from PHI and PHID, mPHI performed the highest specificity (76.5%), by sparing 60.0% of unnecessary biopsies at the cost of missing 11 cases of csPCa. The mPHI outperformed PHI and PHID for overall PCa detection. In terms of csPCa, mPHI exceeds diagnostic performance with a better net benefit in decision curve analysis (DCA) compared with PHI or PHID.ConclusionsWe have developed a modified PHI density (mPHI) model that can sensitively distinguish early-stage csPCa patients within the PSA gray zone.Clinical Trial RegistrationClinicalTrials.gov, NCT04251546.

show abstract

Section: Discussionmentioning

confidence: 99%

Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection

Chen

Qian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Patients with metastatic prostate cancer and having suffered from symptomatic COVID-19 show a greater severity of symptoms and lesser response to treatment modalities highlighting the vicious cycle between COVID-19 and cancer. 124 It was also reported that infection from SARS-CoV-2 hyperactivated the renin-angiotensin system system leading to the activation of proinflammatory pathways and escalated cytokine release that can exacerbate the lower urinary tract symptoms and cause inflammation of the prostate gland causing serious consequences in the future and impact the incidences of prostate cancer. 156 In the case of ovarian cancer, the COVID-19 crisis has severely impeded the patients' care, hospital visits, diagnosis of cancer, treatments, and surgeries.…”

Section: Other Cancersmentioning

confidence: 99%

“…T A B L E 1Brain cancer Dysfunction of immune system and blood-brain barrier, delayed or disrupted treatments, limited scope of clinical trials and subsequent research, neurological and cognitive manifestations[119][120][121] Other cancers Affects prostate cancer through immune hijack and modulation of signaling systems such as RAS pathway, increased proliferation and metastasis in breast cancer due to binding of SAR-CoV-2 virus on lung epithelial cells, upregulation of NF-κB and STAT3 pathways affecting most cancers[122][123][124][125][126] Abbreviations: COVID-19, coronavirus disease 2019; GI, gastrointestinal; SAR-CoV-2, severe acute respiratory syndrome coronavirus 2.…”

mentioning

confidence: 99%

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Ghosh,

Tabassum,

Basu

2023

MedComm – Oncology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic brought about unprecedented challenges to global healthcare systems. Among the most vulnerable populations are cancer patients, who face dilemmas due to their compromised immune systems and the intricate interplay with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. This comprehensive review delves into the multifaceted relationship between COVID‐19 and cancer. Through an analysis of existing literature and clinical data, this review unravels the structural intricacies of the virus and examines its profound implications for cancer patients, thereby bridging the knowledge gap between virology and oncology. The review commences with an introduction regarding the COVID‐19 pandemic and cancer. It then transitions into a detailed examination of the SARS‐CoV‐2 virus and its variants such as Alpha (PANGO lineage B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529 lineage). Subsequently, an insightful analysis of the impact of COVID‐19 on major cancer types (viz., Lung, Colon, Brain, and gastrointestinal cancer) is elaborated. Finally, the therapeutic avenues, oncological care, and management are discussed. The nexus between COVID‐19 and cancer adds a layer of complexity to patient care, emphasizing the importance of tailored approaches for those grappling with both conditions. Amid the landscape defined by the evolving viral strains, this review navigates through the multifaceted implications of COVID‐19 on cancer patients and underscores the significance of integrating virology and oncology.

show abstract

“…This study suggested that it could be useful to investigate whether hormonal therapy, especially for patients with advanced prostate cancer, acts as a protective or risk factor during COVID-19. COVID-19 infection in patients with prostate cancer is a complex scenario with multiple facets ( Sciarra et al, 2020 ; Crocetto et al, 2021 ). A cohort study ( Schmidt et al, 2021 ) suggested that androgen deprivation therapy use was not associated with decreased mortality from SARS-CoV-2 infection in patients with prostate cancer and COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Continuous care needs in patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai: A qualitative study

et al. 2023

View full text Add to dashboard Cite

AimsThis study aimed to investigate the care needs, to clarify the factors affecting the quality of homecare, and to provide reference for constructing a homecare system for patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai.MethodsFrom March to May 2022 when the omicron wave emerged in Shanghai, 50 consecutive patients who received chemotherapy at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, were enrolled, and underwent face-to-face or telephone-based semi-structured interviews regarding continuous care needs. Some of their homecare-givers, caring nurses, and physicians were also interviewed. The Colaizzi method was used for data analysis.ResultsFifty patients, 4 homecare-givers, 4 nurses, and 4 physicians were interviewed. Three themes and six subthemes emerged from analysis of the interviews: The first theme was “Disease management needs,” including needs for knowledge of managing adverse events associated with chemotherapy, and needs for treatment-related information. Patients expressed most concern about not being able to go to the hospital for blood review and disease evaluation in time due to the outbreak. With the COVID-19 pandemic being ongoing, factors such as pandemic panic, inconvenient medical treatment, and worry about hospital cross-infection might reduce disease management for patients with cancer. The second theme was “Medical needs,” including needs for mobile healthcare and needs for medical resources. All interviewees emphasized the importance of mobile healthcare during the COVID-19 pandemic, as access to hospitals was difficult. The third theme was “Spiritual needs,” including demands for psychological counseling and intervention, and needs for spiritual care. Patients and homecare-givers commonly lacked a feeling of security and needed communication, encouragement, and reassurance that medical care could be delivered to them, and patients reported that they very much wanted psychological advice.ConclusionFor patients with cancer receiving chemotherapy during the COVID-19 pandemic, continuous care is greatly needed. Medical personnel should strengthen the healthcare education for patients and their caregivers during hospitalization, and further improve the patients’ information intake rate through Internet-based digital healthcare methods during homecare, to further meet the information needs of patients after discharge from hospital.

show abstract

COVID-19 and Prostate Cancer: a Complex Scenario With Multiple Facets

Cited by 4 publications

References 17 publications

Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection

Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection

COVID‐19 and cancer: Dichotomy of the menacing dilemma

Continuous care needs in patients with cancer receiving chemotherapy during the recent omicron wave of COVID-19 in Shanghai: A qualitative study

Contact Info

Product

Resources

About